This French Startup Cut Cardiac Mortality by 26% — And Just Raised $38 Million

·
Listen to this article~4 min

Implicity, a Paris-based cardiac monitoring startup, just raised $38 million to expand in the US. Their AI platform has shown a 26% reduction in mortality — here's how they plan to scale.

What if a simple software upgrade could save thousands of lives? That's the question Implicity, a Paris-based digital health company, has been answering since 2016. Now they've got $38 million in fresh funding to take that answer global — especially to the United States. ### The Big Raise The round was led by IRIS, a European growth capital firm, with participation from Five Arrows, the alternative assets arm of Rothschild & Co. That's serious institutional backing. And it signals something bigger: investors are betting that AI-driven remote monitoring isn't just a nice-to-have — it's the future of cardiology. ### Why This Matters for Patients Implicity's platform does something deceptively simple: it takes data from cardiac implantable electronic devices (CIEDs) and heart failure monitors, normalizes it, and analyzes it — regardless of which manufacturer made the device. Think of it as a universal translator for heart data. Instead of juggling five different systems, care teams get one clear picture. The results? According to the company, their technology has demonstrated a 26% reduction in mortality and a 4% reduction in hospitalizations. Those aren't small numbers. In a field where every percentage point counts, that's the difference between life and death for thousands of patients. Dr. Arnaud Rosier, an electrophysiologist and co-founder of Implicity, put it best: "I didn't become a physician to manage data — I became one to treat patients. This funding lets us care for patients at scale, catching the information through the noise to provide the best possible care." ### The Problem They're Solving Here's the reality: remote patient monitoring is now the standard of care in cardiology. But with that standard comes a flood of data. Care teams are drowning in alerts, navigating multiple systems, and spending hours triaging information instead of treating patients. It's an administrative crisis that directly impacts patient outcomes. Implicity's AI-driven platform cuts through that noise. It aggregates and analyzes data across the full continuum of care — from cardiac rhythm management to heart failure — and flags only what truly needs attention. That means faster responses to critical events and more time for direct patient care. ### A Growing Trend in European HealthTech Implicity's raise isn't happening in a vacuum. European cardiac care and AI-enabled MedTech are heating up in 2026. Just this year, we've seen: - $6.5 million for Portugal's Hope Care (remote patient monitoring) - $18 million for UK-based TidalSense (AI respiratory diagnostics) - $6.5 million for Swiss startup Xsensio (continuous monitoring) - $91 million for Paris-based DentalMonitoring (AI orthodontic monitoring) - $14 million for Lifeaz (connected defibrillators) - $90 million for FineHeart (advanced heart-failure tech) That's over $226 million flowing into adjacent spaces. France, in particular, is becoming a hotspot for digital health innovation. ### What's Next for Implicity With this new funding, Implicity plans to accelerate its US expansion — a market where they already have a presence. Their platform is used daily at over 250 medical centers, representing more than 120,000 monitored patients. In France, they work with major public hospital networks like AP-HP, CHU Tours, and CHU Grenoble. At Institut Mutualiste Montsouris, they helped scale from 250 to 5,000 patients. Nicolas Herschtel, Partner at IRIS, explained why they invested: "In the evolving HealthTech landscape, long-term success requires a rare combination of robust technology, strict regulatory clearance, and undeniable clinical utility. Implicity has proven to be a highly trusted partner to complex health systems." That trust, combined with hard clinical evidence, makes Implicity one to watch. As they push further into the US market, they're not just selling software — they're offering a solution to a system that's stretched thin. And if the numbers hold up, they might just change how we monitor heart patients everywhere.

📌 Worth Reading Next